Compare EHI & INDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EHI | INDP |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 171.9M |
| IPO Year | 2003 | 2021 |
| Metric | EHI | INDP |
|---|---|---|
| Price | $5.85 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 84.3K | ★ 103.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.75 | $0.92 |
| 52 Week High | $6.70 | $8.57 |
| Indicator | EHI | INDP |
|---|---|---|
| Relative Strength Index (RSI) | 48.01 | 29.35 |
| Support Level | $5.80 | $0.92 |
| Resistance Level | $5.93 | $2.95 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 58.33 | 5.83 |
Western Asset Global High Inc Fd Inc is a non-diversified, closed-end management investment company. Its investment objective is high current income. The Fund's secondary investment objective is total return. It invests in an international portfolio of securities consisting of below-investment-grade fixed income securities, emerging market fixed income securities, and investment-grade fixed income securities. The Fund's investment portfolio comprises sovereign bonds, collateralized mortgage obligations, asset-backed securities, and fixed income securities from different corporate sectors, including financials, energy, consumer discretionary, and industrials, among others.
Indaptus Therapeutics Inc is a clinical biotechnology company that has developed a novel and patented systemically-administered anti-cancer and anti-viral immunotherapy. Its approach is based on the hypothesis that efficient activation of both innate and adaptive immune cells and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system activating signals that can be administered safely intravenously. Its patented technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria, designed to have reduced i.v. toxicity, but largely uncompromised ability to prime or activate many of the cellular components of innate and adaptive immunity. Its candidate, Decoy20 is for patients with solid tumors.